BioVie Inc. Amortization of Debt Discount (Premium)
BioVie Inc. (BIVI) reported Amortization of Debt Discount (Premium) of $11.82 thousand for the 12-month period ending 2025-06-30, per its 10-K filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:AmortizationOfDebtDiscountPremium · last filed 2026-08-13
- BioVie Inc. amortization of debt discount (premium) for the quarter ending 2025-06-30 was $0.00.
- BioVie Inc. amortization of debt discount (premium) for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- BioVie Inc. amortization of debt discount (premium) for the quarter ending 2024-12-31 was $2.36K, a 92.31% decline year-over-year.
- BioVie Inc. amortization of debt discount (premium) for the quarter ending 2024-09-30 was $9.46K, a 75.00% decline year-over-year.
- BioVie Inc. amortization of debt discount (premium) for fiscal 2025 was $11.82K.
- BioVie Inc. amortization of debt discount (premium) for fiscal 2023 was $170.22K, a 71.43% increase from fiscal 2022.
- BioVie Inc. amortization of debt discount (premium) for fiscal 2022 was $99.30K.
- BioVie Inc. amortization of debt discount (premium) for fiscal 2018 was $26.52K.
| Period end | Amortization of Debt Discount (Premium) 3 month | Amortization of Debt Discount (Premium) 6 month | Amortization of Debt Discount (Premium) 9 month | Amortization of Debt Discount (Premium) 9 month as first filed | Amortization of Debt Discount (Premium) 12 month |
|---|---|---|---|---|---|
| 2025-06-30 | $0.00 derived: 10-K 12 month − S-1/A 9 month · filed 2026-08-13 | $0.00 derived: sum of 2 quarters · filed 2026-08-13 | $2.36K derived: sum of 3 quarters · filed 2026-08-13 | $11.82K 10-K · filed 2026-08-13 | |
| 2025-03-31 | $0.00 derived: S-1/A 9 month − 10-Q 6 month · filed 2026-08-06 | $2.36K derived: sum of 2 quarters · filed 2026-08-06 | $11.82K S-1/A · filed 2026-08-06 | -$746.88K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-12-31 | $2.36K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-06 | $11.82K 10-Q · filed 2026-02-06 | -$746.88K derived: sum of 3 quarters · filed 2026-08-06 | $52.01K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-09-30 | $9.46K 10-Q · filed 2025-11-10 | -$749.24K derived: sum of 2 quarters · filed 2026-08-06 | $49.65K derived: sum of 3 quarters · filed 2026-08-06 | $80.38K derived: sum of 4 quarters · filed 2026-08-06 | |
| 2024-06-30 | -$758.70K derived: S-1/A 12 month − 10-Q 9 month · filed 2026-08-06 | $40.19K derived: sum of 2 quarters · filed 2026-08-06 | $70.93K derived: sum of 3 quarters · filed 2026-08-06 | $108.75K S-1/A · filed 2026-08-06 | |
| 2024-03-31 | $798.89K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-05-12 | $829.62K derived: sum of 2 quarters · filed 2025-05-12 | $867.45K 10-Q · filed 2025-05-12 | $92.20K 10-Q · filed 2024-05-14 | $910.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $30.73K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-02-11 | $68.56K 10-Q · filed 2025-02-11 | $111.11K derived: sum of 3 quarters · filed 2025-02-11 | $153.67K derived: sum of 4 quarters · filed 2025-02-11 | |
| 2023-09-30 | $37.83K 10-Q · filed 2024-11-13 | $80.38K derived: sum of 2 quarters · filed 2024-11-13 | $122.93K derived: sum of 3 quarters · filed 2024-11-13 | $165.49K derived: sum of 4 quarters · filed 2024-11-13 | |
| 2023-06-30 | $42.55K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30 | $85.11K derived: sum of 2 quarters · filed 2024-09-30 | $127.67K derived: sum of 3 quarters · filed 2024-09-30 | $170.22K 10-K · filed 2024-09-30 | |
| 2023-03-31 | $42.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-05-14 | $85.11K derived: sum of 2 quarters · filed 2024-05-14 | $127.66K 10-Q · filed 2024-05-14 | $170.22K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $42.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-02-13 | $85.11K 10-Q · filed 2024-02-13 | $127.67K derived: sum of 3 quarters · filed 2024-02-13 | $170.22K derived: sum of 4 quarters · filed 2024-02-13 | |
| 2022-09-30 | $42.55K 10-Q · filed 2023-11-08 | $85.11K derived: sum of 2 quarters · filed 2023-11-08 | $56.74K 10-Q · filed 2022-05-11 | ||
| 2022-06-30 | $42.55K derived: 10-K 12 month − 10-Q 9 month · filed 2023-08-16 | $85.11K derived: sum of 2 quarters · filed 2023-08-16 | $99.30K 10-K · filed 2023-08-16 | ||
| 2022-03-31 | $42.55K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-12 | $56.74K 10-Q · filed 2023-05-12 | |||
| 2021-12-31 | $14.19K 10-Q · filed 2023-02-10 | ||||
| 2019-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-05-10 | $47.99K derived: sum of 2 quarters · filed 2019-05-10 | $51.40K 10-Q · filed 2019-05-10 | ||
| 2018-12-31 | $47.99K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-02-12 | $51.40K 10-Q · filed 2019-02-12 | |||
| 2018-09-30 | $3.41K 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | $26.52K 10-K · filed 2019-09-27 | ||||
| 2017-09-30 | $12.75K 10-Q · filed 2018-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |